Nrodejeneratif bozukluklar (Alzheimer, Parkinson ve Huntington hastalklar, amyotrofik lateral skleroz (ALS), Friedreich ataksisi) Akcier hastalklar (KOAH, astm ve akut solunum gl sendromu) Baklk hastalklar (HIV, otoimmn hastalk) Kardiyovaskler hastalklar (yksek tansiyon, kalp krizi, kolesterol oksidasyonu) Kronik yaa bal hastalklar (katarakt, makler dejenerasyon (sar nokta hastal), iitme bozukluu ve glokom (gz tansiyonu)) Karacier hastal Kistik fibrozis Yalanma srecinin hzlanmas Glutatyon Eksikliinin Nedenleri ve Tans Hava kirlilii, evresel toksik yk, hastalklar, inflamasyon, yalanma ile birlikte hcreler hasar grr ve hcrenin glutatyon ihtiyac artar
Understanding these categories is crucial for creating precise diagnoses and therapies
Cagrilintide in the Broader Peptide Landscape The metabolic peptide field has expanded dramatically, with various compounds targeting different aspects of metabolism: GLP-1 agonists (semaglutide, liraglutide) Single incretin pathway Dual agonists (tirzepatide) GIP + GLP-1 pathways Amylin analogues (cagrilintide) Amylin pathway Triple agonists (retatrutide) GIP + GLP-1 + Glucagon Metabolic modulators (5-Amino-1MQ) NNMT inhibition Each class offers unique mechanisms and potential applications in metabolic research
Li Y, Chen H, Xie X, Yang B, Wang X, Zhang J, et al